Company intelligence / Profile preview
bluebird bio, Inc.
Somerville* or Cambridge**, Massachusetts, United Statesmybluebirdsupport.com ↗
- Ownership
- Public · BLUE
- Employees
- ~264
- Development stage
- Commercial
01
Overview
bluebird bio has achieved FDA approval for three ex vivo lentiviral vector-based gene therapies—ZYNTEGLO for transfusion-dependent beta thalassemia, SKYSONA for cerebral adrenoleukodystrophy, and LYFGENIA for sickle cell disease. The company has the largest clinical data set in ex vivo gene therapy and continues to focus on commercializing these products while advancing access agreements with payers.[5][6][8]
- Therapeutic areas
- HematologyNeurology
- Modalities
- Ex vivo gene therapy using lentiviral vectors[6][9]
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
Inhibrix – exclusive license agreement on CAR-T sdAb platform(2019) [1]Celgene – collaboration on oncology/novel therapies(2013) [1]
04
Financials
- Market cap
- $48.7M
- Total revenue
- $38.7M
- Enterprise value
- $158.1M
Beyond the preview
Go deeper on bluebird bio, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bluebird bio, Inc..